Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...

Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks ...

Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...

In trading on Tuesday, shares of Biohaven Ltd (Symbol: BHVN) crossed above their 200 day moving average of $40.76, changing hands as high as $42.68 per share. Biohaven Ltd shares are currently ...

(MENAFN- PR Newswire) Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, "Our NDA filing is the culmination of over 8 years of clinical research and represents an ...